dramatic weight loss. Subsequent workup yields normal neurological examination findings, and when performed, MRI is negative for structural compression via bone or tumors in classic TN. The role of imaging in patients with TN is somewhat controversial, as large evidence-based studies have provided inconsistent results and varying degrees of sensitivity and specificity. Thus, the American Academy of Neurology and the European Federation of Neurological Societies (AAN/EFNS) has concluded that there is insufficient evidence to support or refute the utility of MRI to identify neurovascular compression in classic TN. 11 If routine imaging studies are obtained, underlying structural etiologies for the pain will appear in about 15% of patients with TN. In certain demyelinating disorders such as multiple sclerosis, demyelination of the trigeminal nerve can be seen, although some instances reveal vascular compression as well. 20 Current available treatment options include medical management, surgical intervention, or stereotactic radiosurgery. Pain control is initiated using medication, most often an anticonvulsant. Medical treatment options commonly include carbamazepine as the initial drug of choice, but other anticonvulsants, such as gabapentin, phenytoin, oxcarbazepine, lamotrigine, and topiramate, may be used as well. 5 Often patients will poorly tolerate the medication or have pain refractory to medical management. In this setting, the patient can have more invasive treatment such as surgical intervention, which is classified as either destructive to the trigeminal nerve or nondestructive. Destructive procedures include rhizotomy, balloon compression, and radiofrequency thermocoagulation. 22 Rhizotomy involves injecting an agent directly into the affected nerve branch. In balloon compression a small balloon can be inserted into the nerve branches to compress the nerve within a bony foramen. Common side effects of the aforementioned surgical options include sensory loss (50%), dysesthesias (6%), anesthesia dolorosa (4%), and corneal numbness (4%). 11, 22, 30 Another, often more favorable, nondestructive surgical option is microvascular decompression (MVD). This procedure often leads to very good, sustained pain relief and is highly recommended for younger patients or those with few to no comorbidities. While the risk of morbidity is known to be low, MVD remains a major neurosurgical procedure that involves craniotomy and can require days of inpatient recovery postprocedure. Side effects include CSF leakage, hearing loss, hemorrhage, numbness, and facial weakness. Complications most often include aseptic meningitis (11%) and hearing loss (10%), as well as sensory loss (7%).
11 High-dose stereotactic radiosurgery has been used since the 1970s and is very effective for the treatment of TN. In patients with recurrent or refractory pain, repeat radiosurgery has also been found to be effective. Two courses are often the limit as there have been concerns about tolerance of the brainstem, as well as the nerve itself, to further radiotherapy. Radiation-induced trigeminal nerve or pontine necrosis and anesthesia dolorosa are both feared complications among radiosurgery practitioners.
In this case report we describe the interesting course of a young patient who underwent 3 separate Gamma Knife radiosurgery (GKRS) courses to the same nerve for the successful treatment of refractory TN. We also discuss the literature, including a similar report, and highlight favorable characteristics and situations in which multiple GKRSs can be performed safely and with positive outcomes.
case report

History and Examination
A 38-year-old man initially presented to his primary care physician 14 years earlier, reporting a 3-year history of right jaw and tongue pain. He described his pain as "a nail being stuck into my tongue and jaw." The pain lasted anywhere from a few seconds up to half a minute maximum. The frequency of his pain was irregular, occurring as much as several times in a day to as infrequently as 2-3 times a week. Shaving, eating, or talking usually elicited pain. The patient was healthy without any neurological or other medical conditions. At the time, MRI was performed, which incidentally revealed a left clival mass, which was biopsied 2 months later and was diagnosed as Paget's disease. He remained asymptomatic of the Paget's disease and was placed on 200 mg of hydroxyzine 3 times a day. He did not achieve any relief, however, and was placed on 200 mg of carbamazepine 3 times a day for a year after presenting to his primary physician. He continued to require increasing doses of the carbamazepine and ultimately underwent balloon compression 16 months after presentation to his primary physician. He reported that his initial neurosurgeon, who worked at an outside facility, deferred MVD as the first-line treatment both because of its invasive nature and because of neurosurgeon preference. The balloon compression relieved his pain, and he required no medication until, unfortunately, the pain returned about 6 months later. He was again placed on carbamazepine at the prior dosage, although it was eventually raised to 300 mg 3 times a day with very minimal relief of his symptoms. His neurosurgeon then referred him to radiation oncology. At the time of initial presentation to our department, 15 months had passed since his surgery, 10 of which he was symptomatic. After a detailed discussion, he elected to undergo GKRS.
First GKRS and Postoperative Course
He received 85 Gy to the 100% isodose line to the proximal trigeminal nerve in two 4-mm shots, the first of which was immediately adjacent to the lateral pons. Following GKRS, the patient had significant pain relief, and at the 1-month follow-up, he was slowly decreasing his pain medications (200 mg 2 times a day). Available physical examination follow-up reports noted "very mild diminished sensation along the body of the mandible."
Unfortunately, 5 months after GKRS, his pain recurred and, in fact, was more severe. His carbamazepine dose was raised to 800 mg daily without any abatement. The pain, which was rated 1-2/10 with episodes up to 10/10, was unresponsive to any medications or intervention. Since he had sustained relief after the initial GKRS with minimal response to medical management, the decision was made to proceed with another GKRS.
Second GKRS and Postoperative Course
At 6 months after the first GKRS, a total of 70 Gy was administered to the 100% isodose line in two 4-mm shots just distal to the site of emergence of the right trigeminal nerve. Following the second GKRS, the patient did very well with only occasional twinges of pain, which, according to the patient, never returned to pre-procedure levels. The diminished sensation remained stable without further neurological symptoms. Neurological examination was essentially unremarkable, except for an area of perceived numbness from the lateral canthus to the lateral zygomatic arch in the V2 distribution, with no other sensory, motor, or cerebellar deficits. Corneal reflex testing was intact bilaterally. There was no symptom or sign of facial weakness, decrease in hearing, or ocular dryness. There were no signs of deafferentation pain syndrome. He was seen annually for 7 years without any change or increase in symptoms. Ultimately, 9 years after the second GKRS, the patient had 10/10, severe lancinating pain that recurred in the right-sided roof of the mouth, radiating through to the right mandible. He reported right facial numbness, which at the time was severe and located over the right zygomatic arch, along with paresthesia-like sensations around the right eye. There was neither facial asymmetry nor deficit in the facial muscles; corneal reflex testing remained intact. At the time, the patient was not agreeable to restarting medications given their side effects. Since he had long-term pain relief after the second GKRS, relative intolerance to medications, and the possibility of treating the nerve more distally, he underwent a third course of GKRS.
Third GKRS and Postoperative Course
The right trigeminal nerve was treated with a single 4-mm shot delivering a dose of 70 Gy to the 100% isodose line. To avoid overlap with prior treatments, the target was made to the anterior portion of the right trigeminal nerve root. The composite dose delivered is pictured in Fig. 1 . Upon follow-up 1 year later, the patient was without pain and medication free. The minimal numbness in the right side of his face was still present along the V2 sensory distributions and had not increased in severity. There were no signs of deafferentation, anesthesia dolorosa, corneal reflex impairment, or facial muscle paralysis. According to the patient, numbness to light touch in the above distribution was not bothersome or progressing. At the 3-year follow-up after the third GKRS, the patient was pain free and without medications; however, he now noticed the minor decreased sensation to light touch along the V1 distribution as well, just posterior to the right lateral side of the hairline. During the patient's 5-, 113-, and 36-month pain-free durations after each GKRS, his Barrow Neurological Institute (BNI) Facial Hypesthesia Scale score was never above II, as he had mild facial numbness that was not bothersome. 33 A table describing both the latency until pain relief after each surgical and GKRS procedure, as well as the duration of pain relief achieved for each of these procedures, can be seen in Table 1 .
This patient underwent 3 GKRS courses to the same nerve with continued duration of pain response and minimal side effects.
discussion
The pathophysiology of TN has been presumed attributable to vascular compression in the root entry zone of the trigeminal nerve in the midpons, leading to subsequent demyelination. This theory has led to the development of MVD surgery, in which a retromastoid craniectomy is performed to relieve pressure on the nerve. 18 Multiple surgical interventions are now possible, including glycerol rhizotomy, radiofrequency ablation, and percutaneous balloon compression; however, surgical intervention is commonly considered secondary to medical interventions because of surgical morbidities. 34 While MVD is the most invasive treatment option, it remains the least likely to damage the nerve. As with surgery, medical management can have significant side effects, including bone marrow suppression and hepatic dysfunction in addition to cognitive impairment.
Stereotactic radiosurgery has emerged as an effective therapeutic alternative with comparatively decreased side effects. Lars Leksell originally described GKRS as a suc- cessful treatment for patients with TN in 1971. 5 The efficacy of GKRS for TN pain is believed to be attributable to the induction of axonal degeneration. Doses upwards of 80-100 Gy can produce visible axonal degeneration and edema of the trigeminal nerve. Currently, GKRS plans commonly use targets involving the nerve entry zone rather than the gasserian ganglia, the trigeminal nerve cell bodies. Previously, studies utilizing targeting of the trigeminal ganglion had very poor rates of pain relief and mild success rates. 5, 16, 28 The belief behind targeting the root entry zone is that this area involves a transition zone in the axons from peripheral to central myelin, which in theory is believed to be more susceptible to radiation. 33 Several articles have documented histopathological evidence of axonal degeneration and fibrosis after GKRS.
1,15
Trigeminal neuralgia treatment responses are evaluated on the standardized BNI pain intensity scale, in which scores of I-III are considered good control. 5 Data arranged in Chin et al. revealed that after GKRS up to 93% of patients experience durable pain relief ranging from no trigeminal pain to durable pain control on medication. In a comparison of 8 trials evaluating TN outcomes for initial GKRS, the percentage of patients achieving good control ranged from 69% to 94%, with up to 72% of patients requiring no medications.
Gamma Knife radiosurgery continues to be a safe, efficacious treatment for both medically and surgically refractory TN. 9, 17 Refractory TN presents a difficult clinical situation, as it is well established that a patient's initial surgical intervention remains the most successful, with subsequent surgical interventions offering diminishing returns. Overall, the success of repeat GKRS with regard to pain relief is estimated to be around 60%-70% in numerous studies. 10, 25 However, patients undergoing GKRS have better response rates if they have not undergone a prior surgical intervention. 23 Studies on the GKRS doses used for TN have reported that doses ≥ 70 Gy provide better pain control than doses < 70 Gy. Doses over 100 Gy are likely to result in trigeminal nerve necrosis.
15 Some institutions will use 2 isocenters to treat a larger target volume of the trigeminal nerve. In a 2005 study from our institution, we found that 2-isocenter dose plans were associated with significantly greater improvements in the BNI score than 1-isocenter dose plans, with no increase in neurological morbidities. 2 Updated published results revealed an increased response rate with dose escalation and 2 isocenters. 21 While these results differ from those in a prospective randomized controlled trial by Flickinger et al., the difference is likely attributable to a difference in isocenter placement. 8 Morbidini-Gaffney et al. reported greater overlap of isocenters than the 3-to 5-mm separation described by Flickinger et al., which allowed a shorter nerve length and/or volume to be treated to a higher dose. 21 Again, low rates of tolerable numbness and paresthesias continued to occur in the Morbidini-Gaffney et al. study compared with the rates seen by Pollock et al. (11% vs 20%, respectively) . 27 Few studies have long-term data on patient outcomes and quality of life following GKRS for TN. An article from the University of Maryland with a 5-year follow-up has reiterated the above-described findings, reporting a larger number of patients achieving durable pain control if they had not undergone prior surgical procedures. Response duration was significantly better for those who had no prior invasive treatment than for those in whom a previous surgical intervention had failed (32 vs 21 months, p < 0.02). 6 The duration of an initial response after GKRS is a significant factor predicting the level of response to subsequent GKRS. 13, 26, 32 There is very limited experience in the literature regarding patients receiving a third course of GKRS for refractory TN. To our knowledge, only 2 other papers have described patients with a third course of GKRS for TN. 10, 14 Gellner et al. reports on 2 patients who had each undergone a third and fourth GKRS treatment with single isocenters; however, very little information is reported about these patients. 10 One patient underwent a third GKRS 2 years after a second radiosurgical procedure and a fourth GKRS 12 months later. The other patient also underwent a third GKRS 2 years after a second and later underwent thermal coagulation and a subsequent fourth GKRS in a 5-year period. There are no other available data regarding these patients' clinical outcomes.
A paper by Jones et al. details the case of a 72-yearold man who underwent a third GKRS, a case that has some similarities with our patient.
14 The authors describe a patient who failed initial medical management as well as radiofrequency gangliotomy between his first and second GKRS. Initially, he was treated with 42 Gy to the trigeminal root entry zone to the 50% isodose line (max point dose 84 Gy). Failed pain control was documented 2 months after the initial GKRS. A second radiosurgical procedure was performed 11 months after the initial GKRS. Treatment was again directed to the proximal nerve root entry zone, but a dose of 27 Gy to the 50% isodose line was delivered (max point dose 54 Gy; a 36% dose reduction). The patient had 6.5 months of pain relief on no medications and underwent a third GKRS 17 months after his initial GKRS. The third treatment involved dose delivery to a target "millimeters distal to the prior target" and prescribed 20 Gy to the 50% isodose line (max point dose of 40 Gy). As in our case, a more distal target was chosen to decrease neural toxicity and the risk of necrosis. However, after 3 symptom-free months, pain again recurred and was treated surgically with MVD. The authors reported on a 6-month follow-up from the last GKRS in their conclusion, with a total of 26 months since the patient's initial GKRS treatment.
The present case report and the one by Jones et al. are the only 2 articles to date that provide detailed information on the treatments and outcomes in patients who have undergone a third GKRS treatment. However, there are significant differences between these 2 cases. In our patient, there was only 1 surgical treatment prior to the first GKRS. Jones et al. describes the need for 2 surgical interventions, each due to GKRS failure-one between the first and second GKRS and one after the third GKRS. As noted previously, GKRS has improved effectiveness with a lower number of prior surgical interventions. 4 Although the initial surgical treatment failed in our patient, he continued to have longer periods of pain control between each GKRS and did not require any interventions or medica-tions after the third GKRS. Importantly, a longer followup after the final treatment was furnished in our case report, which impacts the reporting of late toxicities.
Considering the technical aspects, our treatment plans differed from those described by Jones et al. in that we continued to use high doses in each subsequent radiosurgical procedure, with 2 isocenters continued in the second GKRS and moving to 1 isocenter with an anterior shift of the target in the third GKRS to avoid necrosis. The distance between shots was 3 mm for the initial 2 treatments. The third course involved delivery of a single shot 5 mm anterior to prior treatments at the entrance to Meckel's cave. The maximum point dose to the trigeminal nerve was located midway between the brainstem and the gasserian ganglion, and it was estimated at 150 Gy, with the patient receiving most of this dose from the first 2 treatments. The accumulated dose to the gasserian ganglion was estimated at 50-70 Gy, with most of the dose having been contributed by the third GKRS. Despite repeated high doses to the nerve, there was no increase in bothersome or significant facial numbness or paresthesias. Importantly, our patient had no side effects or necrosis in the brain. However, concern about pontine necrosis motivated us to place the third course shot quite anterior to the prior shots. In full, the composite maximum point dose to the brainstem was 108.7 Gy. According to Chin and Regine, patients who undergo repeat GKRS have higher incidences of facial numbness, but they report no increase in dysesthesias or radiation necrosis, which was demonstrated in our case. 5 A significant concern in treating our patient was deafferentation pain or anesthesia dolorosa. According to an article by Pollock, radiosurgery should be classified as a destructive procedure, and the success of GKRS is directly related to the degree of trigeminal nerve injury. 24 These assertions have been reiterated in the literature. 27, 29, 31 Therefore, sufficient damage is required to achieve lasting pain relief, but this increased injury must be balanced with the greater risk of deafferentation syndromes. Anesthesia dolorosa is experienced as intractable severe pain in an area of numbness. This chronic pain syndrome is very difficult to control and is believed to be attributable to deafferentation-releasing second-order neurons, which generate spontaneous pain signals without stimulus. 30 Albeit rare, anesthesia dolorosa can result from both surgical and radiosurgical therapies for TN with different incidences. For patients who are status post-trigeminal rhizotomy, incidence is estimated at 2.4%. 30 In our review, extrapolating from articles in which patients with TN were treated with GKRS and there were documented cases of anesthesia dolorosa, we estimate the risk of anesthesia dolorosa to be between 0.005% and 0.03%. 3, 19 The patient in our case report did not develop anesthesia dolorosa and has had continued pain relief following 3 GKRS procedures, with an estimated total dose of 150 Gy to the trigeminal nerve. A 2004 abstract from ASTRO (American Society for Radiation Oncology) reported that repeat GKRS with median cumulative doses upwards of 180 Gy produced successful results with a higher propensity to be off medications than at lower doses with no increase in deafferentation pain incidence. 7 Nevertheless, it remains that the data on anesthesia dolorosa are scarce in the literature, which limits an accurate estimation of risk.
conclusions
In summary, we present a case in which the trigeminal nerve was treated using multiple courses of GKRS with minimal toxicity and continuing effectiveness. Important considerations in offering further GKRS treatment to patients with TN refractory to previous radiosurgical procedures include response to medical management, number of prior surgical interventions, and duration of response to prior GKRS. Technical aspects of treatment delivery should be meticulously defined and may need adjustment from the standard protocol. A shot can be placed anteriorly to reduce the risk of trigeminal or brainstem necrosis without needing to reduce dose and compromise treatment effectiveness. A well-selected patient can be safely treated with multiple courses of GKRS without decreasing subsequent target doses.
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